Can Revance Therapeutics (RVNC) Climb 98.64% to Reach the Level Wall Street Analysts Expect?

Shares of Revance Therapeutics, Inc. (RVNC) have gained 73.2% over the past four weeks to close the last trading session at $6.60, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $13.11 indicates a potential upside of 98.6%. The mean estimate comprises nine short-term price targets with a standard deviation of $6.60. While the lowest estimate of $8 indicates a 21.2% increase fro ...